Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Evaluation of Oral Enzastaurin HCl in Second-and Third- Line Treatment of Patients With Non-Small Cell Lung Cancer

NCT00105092 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT00105092
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00105092 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Evaluation of Oral Enzastaurin HCl in Second-and Third- Line Treatment of Patients With Non-Small Cell Lung Cancer
Lead sponsor
Eli Lilly and Company
Phase
Phase 2
Overall status
Completed
Start date
March 31, 2005
Completion date
February 28, 2007
Enrollment
50
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

non-small-cell lung carcinoma